Man Group plc Purchases New Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Man Group plc acquired a new stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,454 shares of the company's stock, valued at approximately $217,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of SI-BONE by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock valued at $328,000 after purchasing an additional 988 shares during the last quarter. Invesco Ltd. grew its stake in SI-BONE by 8.9% during the 4th quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after purchasing an additional 1,413 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after purchasing an additional 1,683 shares during the period. Barclays PLC raised its stake in shares of SI-BONE by 2.7% in the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock worth $1,391,000 after purchasing an additional 2,589 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in SI-BONE by 6.2% in the fourth quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock valued at $782,000 after purchasing an additional 3,250 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Truist Financial lifted their target price on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th.

SI-BONE Stock Down 0.6%

Shares of SIBN traded down $0.12 during mid-day trading on Friday, hitting $18.86. 437,967 shares of the company's stock were exchanged, compared to its average volume of 377,894. The stock has a market cap of $803.72 million, a price-to-earnings ratio of -20.50 and a beta of 0.82. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm has a fifty day moving average of $15.62 and a two-hundred day moving average of $15.34. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, sell-side analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Insider Transactions at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 2,424 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $19.48, for a total transaction of $47,219.52. Following the transaction, the chief financial officer now owns 222,083 shares in the company, valued at approximately $4,326,176.84. This represents a 1.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 92,565 shares of company stock worth $1,669,871. Insiders own 4.00% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.